HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Jafra Cosmetics International

This article was originally published in The Rose Sheet

Executive Summary

Net sales up 2% to $98.1 mil. in second quarter, led by gains of 16% and 11%, respectively, in the U.S. and Europe. Sales in U.S. Hispanic market advanced 19% year-to-date, Westlake Village, Calif.-based direct seller noted. Domestic increase was attributed to productivity-based changes in the selling program and new products. Local currency sales in Mexico, the firm's largest market, were flat for the period. Net income doubled during the quarter to $4 mil., reflecting higher operating profits and a lower effective tax rate. Jafra owner Clayton Dubilier & Rice seeking purchase offers for the cosmetics business, which had 2001 sales of $380 mil. and net income of $15.8 mil. A CDR-managed fund bought Jafra from Gillette in 1998...

You may also be interested in...



FDA Slacking In NDI Notification Enforcement; COVID-19 'Is Not An Excuse’ – NPA

In a statement submitted to the Senate Finance Committee, Natural Products Association CEO Dan Fabricant suggests two ways of improving compliance with new dietary ingredient notification requirements at negligible expense to the US FDA.

Finance Watch: Four IPOs In One Week, And Legend Is Year’s Largest So Far

Public Company Edition: Legend Biotech raised $424m in its US public market debut. Also, Pfizer commits up to $500m for equity investments and Allogene capitalizes on ASCO with a $550m offering.

FDA Says GMP Lapses In Facilities And Production Areas More Common For Cell And Gene Therapies

US FDA investigators are more likely to cite cell and gene therapy manufacturers for facilities and production deficiencies, agency says, while industry reports difficulties complying with drug GMP requirements that are not always applicable to cell and gene therapies.

UsernamePublicRestriction

Register

PL000723

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel